Cargando…
Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging
OBJECTIVES: The pharmacological stress test with vasodilator agents is an alternative cardiological diagnostic tool for patients with contraindications to the classical stress test provided by physical activity during single-photon emission computed tomography (SPECT) myocardial perfusion imaging (M...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284185/ https://www.ncbi.nlm.nih.gov/pubmed/37337782 http://dx.doi.org/10.4274/mirt.galenos.2022.72593 |
_version_ | 1785061352827518976 |
---|---|
author | Roczniak, Jan Bączalska, Justyna Kanclerz, Gabriela Zielińska, Weronika Ożga, Joanna Cymerman, Błażej Stępień, Agnieszka Kostkiewicz, Magdalena Holcman, Katarzyna |
author_facet | Roczniak, Jan Bączalska, Justyna Kanclerz, Gabriela Zielińska, Weronika Ożga, Joanna Cymerman, Błażej Stępień, Agnieszka Kostkiewicz, Magdalena Holcman, Katarzyna |
author_sort | Roczniak, Jan |
collection | PubMed |
description | OBJECTIVES: The pharmacological stress test with vasodilator agents is an alternative cardiological diagnostic tool for patients with contraindications to the classical stress test provided by physical activity during single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). The study compared the frequency of the side effects of regadenoson and dipyridamole during a SPECT MPI. METHODS: This retrospective study included data of 283 consecutive patients who underwent pharmacological stress tests in years 2015-2020. The study group consisted of 240 patients who had received dipyridamole and 43 patients who had received regadenoson. The collected data included the patients’ characteristics, the occurrence of side effects (divided into mild: headache, vertigo, nausea, vomiting, dyspnea, chest discomfort, hot flushes, general weakness and severe: bradycardia, hypotension, loss of consciousness), and blood pressure values/measurements. RESULTS: Overall, complications occurred relatively often (regadenoson: 23.2%, dipirydamol: 26.7%, p=0.639). Procedure discontinuation was necessary in 0.7% of examinations, whereas pharmacological support was necessary in 4.7%. There was no difference in the prevalence of mild (regadenoson: 16.2%, dipirydamol: 18.3%, p=0.747) and severe complications (regadenoson: 11.6%, dipyridamole: 15.0%, p=0.563). However, regadenoson has been found to cause a significantly smaller mean decrease of systolic blood pressure (SBP) (regadenoson: -2.6±10.0 mmHg, dipyridamole: -8.7±9.6 mmHg, p=0.002), diastolic blood pressure (DBP) (regadenoson: -0.9±5.4 mmHg, dipyridamole: -3.6±6.2 mmHg, p=0.032), as well as mean arterial pressure (MAP) (regadenoson: -1.5±5.6 mmHg, dipyridamole: -5.4±6.5 mmHg, p=0.001). CONCLUSION: Regadenoson and dipyridamole presented a similar safety profile during SPECT MPI. However, regadenoson has been found to cause significantly smaller decreases in SBP, DBP, and MAP. |
format | Online Article Text |
id | pubmed-10284185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Galenos Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-102841852023-06-22 Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging Roczniak, Jan Bączalska, Justyna Kanclerz, Gabriela Zielińska, Weronika Ożga, Joanna Cymerman, Błażej Stępień, Agnieszka Kostkiewicz, Magdalena Holcman, Katarzyna Mol Imaging Radionucl Ther Original Article OBJECTIVES: The pharmacological stress test with vasodilator agents is an alternative cardiological diagnostic tool for patients with contraindications to the classical stress test provided by physical activity during single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). The study compared the frequency of the side effects of regadenoson and dipyridamole during a SPECT MPI. METHODS: This retrospective study included data of 283 consecutive patients who underwent pharmacological stress tests in years 2015-2020. The study group consisted of 240 patients who had received dipyridamole and 43 patients who had received regadenoson. The collected data included the patients’ characteristics, the occurrence of side effects (divided into mild: headache, vertigo, nausea, vomiting, dyspnea, chest discomfort, hot flushes, general weakness and severe: bradycardia, hypotension, loss of consciousness), and blood pressure values/measurements. RESULTS: Overall, complications occurred relatively often (regadenoson: 23.2%, dipirydamol: 26.7%, p=0.639). Procedure discontinuation was necessary in 0.7% of examinations, whereas pharmacological support was necessary in 4.7%. There was no difference in the prevalence of mild (regadenoson: 16.2%, dipirydamol: 18.3%, p=0.747) and severe complications (regadenoson: 11.6%, dipyridamole: 15.0%, p=0.563). However, regadenoson has been found to cause a significantly smaller mean decrease of systolic blood pressure (SBP) (regadenoson: -2.6±10.0 mmHg, dipyridamole: -8.7±9.6 mmHg, p=0.002), diastolic blood pressure (DBP) (regadenoson: -0.9±5.4 mmHg, dipyridamole: -3.6±6.2 mmHg, p=0.032), as well as mean arterial pressure (MAP) (regadenoson: -1.5±5.6 mmHg, dipyridamole: -5.4±6.5 mmHg, p=0.001). CONCLUSION: Regadenoson and dipyridamole presented a similar safety profile during SPECT MPI. However, regadenoson has been found to cause significantly smaller decreases in SBP, DBP, and MAP. Galenos Publishing 2023-06 2023-06-20 /pmc/articles/PMC10284185/ /pubmed/37337782 http://dx.doi.org/10.4274/mirt.galenos.2022.72593 Text en ©Copyright 2023 by the Turkish Society of Nuclear Medicine / Molecular Imaging and Radionuclide Therapy published by Galenos Publishing House. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Roczniak, Jan Bączalska, Justyna Kanclerz, Gabriela Zielińska, Weronika Ożga, Joanna Cymerman, Błażej Stępień, Agnieszka Kostkiewicz, Magdalena Holcman, Katarzyna Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging |
title | Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging |
title_full | Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging |
title_fullStr | Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging |
title_full_unstemmed | Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging |
title_short | Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging |
title_sort | comparison of regadenoson and dipyridamole safety profiles during stress myocardial perfusion imaging |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284185/ https://www.ncbi.nlm.nih.gov/pubmed/37337782 http://dx.doi.org/10.4274/mirt.galenos.2022.72593 |
work_keys_str_mv | AT roczniakjan comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging AT baczalskajustyna comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging AT kanclerzgabriela comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging AT zielinskaweronika comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging AT ozgajoanna comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging AT cymermanbłazej comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging AT stepienagnieszka comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging AT kostkiewiczmagdalena comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging AT holcmankatarzyna comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging |